California Comparative Medicine Training Specialist
About the job
- A bachelor’s degree with 6+ years of relevant experience or a master’s degree with 3+ years of relevant experience.
- Demonstrated knowledge of contemporary laboratory animal science programs and animal welfare regulations.
- At least 3 years of experience developing, coordinating, and delivering classroom, technical, and hands-on training programs.
- Experience supporting laboratory animal research operations, vivarium management, training programs, or regulatory compliance activities.
- Knowledge of laboratory animal care and use programs, research procedures, animal welfare regulations, and institutional oversight processes.
- Strong written, verbal, and interpersonal communication skills to collaborate across diverse stakeholder groups.
- Organizational skills to manage multiple priorities in a regulated environment.
- AALAS certification at Laboratory Animal Technician level or higher.
- Serve as the primary Comparative Medicine trainer for California research sites, including Irvine and the AbbVie Bay Area campus.
- Develop, coordinate, and deliver instructor-led, hands-on, and technical training programs related to laboratory animal science, animal care and use, vivarium operations, and research procedures.
- Coordinate blended and hybrid learning models that combine in-person vivarium instruction with virtual instructor-led sessions.
- Integrate the Learning Management System by delivering microlearning modules, e-learning courses, and on-demand video libraries.
- Use scenario-based quizzes, branching simulations, and digital badging or credentials to reinforce knowledge retention and validate competency.
- Provide mobile learning tools, including quick-reference job aids, Standard Operating Procedure videos, and refresher content accessible on tablets and mobile devices in the vivarium.
- Use adaptive learning platforms and artificial-intelligence-driven content sequencing to tailor training pathways to learner proficiency and role requirements.
- Track training completion, competency assessments, and skill gaps through data analytics and learning dashboards.
- Support recorded procedural video libraries and screen-capture demonstrations for technique standardization and onboarding.
- Partner with Comparative Medicine leadership and functional stakeholders to assess training needs, establish priorities, and support workforce development initiatives.
- Coordinate training schedules, manage training requests, and ensure completion of onboarding and continuing education activities.
- Evaluate trainee competencies and collaborate with managers and subject matter experts to ensure personnel are qualified for assigned responsibilities.
- Maintain training records and documentation for regulatory compliance, audit readiness, and operational excellence.
- Support global training initiatives and contribute technical expertise to Comparative Medicine learning programs and best practices.
- Partner with Comparative Medicine leadership, Environmental Health and Safety, and Facilities to promote safe and compliant animal care and research operations.
- Support facility readiness for inspections, site visits, and accreditation activities, including USDA, AAALAC International, DEA, and internal compliance reviews.
- Monitor evolving regulatory requirements, industry standards, and best practices related to laboratory animal science and animal welfare.
- Identify operational risks and training gaps and collaborate with leadership to develop and implement mitigation strategies.
- Communicate operational issues, compliance concerns, and training program performance to site leadership.
- Coordinate vivarium access requests, verify training prerequisites, assign required training, and conduct facility orientation programs.
- Maintain accurate records associated with access authorization and training compliance.
- Administer Comparative Medicine training curricula, training matrices, onboarding programs, and training assignments.
- Serve as Global Super Administrator for the AALAS Learning Library, including user administration, training assignments, compliance monitoring, annual renewals, reporting, and stakeholder communications.
- Support maintenance and continuous improvement of training content and learning management processes.
- Coordinate review, revision, and publication of Comparative Medicine Standard Operating Procedure procedures and related controlled documents.
- Support document governance activities, including version control, change management, and publication through approved quality systems.
- Partner with subject matter experts to keep procedures current, accurate, and compliant with applicable regulations and organizational standards.
- Serve as a member of the Post Approval Monitoring Committee.
- Maintain Comparative Medicine distribution lists and communication resources.
- Support special projects, process improvement initiatives, and other operational activities as assigned.
- A bachelor’s degree in Laboratory Animal Science, Animal Science, Biology, Veterinary Technology, or a related scientific discipline.
- Extensive experience delivering technical and hands-on training in laboratory animal science, research operations, or a related field.
- Experience evaluating trainee competency and maintaining compliant training documentation.
- Registered Veterinary Technician designation.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approval of JUVMO on September 28, 2026 opens a new Parkinson's launch.
- AbbVie partnered with Valkai on September 29, 2026 to speed clinical development.
- ADARx's September 2026 deal gives AbbVie siRNA options across neuroscience, immunology, and oncology.
What critics are saying
- AbbVie still faces Humira antitrust injunction claims after October 1, 2026 federal trimming.
- AbbVie's March 2026 appeal keeps Humira pricing litigation alive and expensive.
- Humira's biosimilar erosion remains existential if Skyrizi and Rinvoq growth slows.
What makes AbbVie unique
- AbbVie owns first-in-class immunology, neuroscience, and aesthetics franchises, spanning drugs and procedures.
- Juvmo, approved September 25, 2026, is the first selective D1/D5 Parkinson's agonist.
- RINVOQ now holds 11 EU indications, reinforcing AbbVie's platform breadth beyond Humira.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%About adarx Pharmaceuticals. ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. BiopharmaWatch has developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to its wholly-owned programs, BiopharmaWatch has entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
Migraine annual economic and quality-of-life burden in UK. Migraine affects an estimated 280,000 people across Greater Manchester and creates an annual economic and quality-of-life burden of around £870m, according to a report from Health Innovation Manchester and AbbVie UK. The report, based on linked healthcare data, health economic modelling, pathway analysis and patient and healthcare professional insights, estimates that £546m of the burden relates to quality-of-life impacts, £295m to lost productivity and £29m to direct healthcare costs. It found that only around one-third of people thought to have migraine are captured in recorded diagnosed or actively treated populations, although gaps in diagnosis and routine recording mean the true burden may be higher. The analysis also identified variation in diagnosis, treatment and access to specialist care. Of patients newly diagnosed between 2019 and 2024, 55% received preventative treatment, while around 1% reached fourth-line treatment during the evaluation period. The report recommends a standardised NICE-aligned migraine pathway, greater capacity in primary and community care, a population health approach to identifying unmet need, and more consistent treatment review and escalation. Laura Rooney, Deputy Chief Executive at Health Innovation Manchester, said: "Many people are living without a diagnosis, navigating fragmented services or waiting too long for their treatment to be reviewed and optimised." The report was produced through a collaborative working project between Health Innovation Manchester and AbbVie. It concludes that the findings could inform migraine care planning elsewhere in the UK, although the analysis is specifically based on Greater Manchester.
Abbott Laboratories has launched SimpleScreen CRC in the US, an FDA-approved blood-based colorectal cancer screening test for average-risk adults who decline traditional screening methods. The company's share price has fallen 10.2% over one month, though it remains up 9.5% over 90 days. The one-year total shareholder return stands at negative 22.9%, suggesting investors are reassessing growth potential around the current $100.95 share price. The most followed valuation narrative points to a fair value of $120.26, implying the stock is 16% undervalued. This valuation factors in the scaling of Abbott's cancer diagnostics portfolio and expected contributions of approximately $3 billion in 2026 sales. However, the company faces pressure from ongoing nutrition legal settlements and higher expansion spending for its Libre product line.
AbbVie partners with Valkai to apply advanced AI across targeted areas of clinical development. Science · SEP 29, 2026 PR Newswire AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across... * AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development * AbbVie is committed to integrating AI throughout the drug development journey to advance scientific innovation, strengthen operations and improve outcomes for patients NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ - AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients. Through its partnership with Valkai, AbbVie will deploy purpose-built AI capabilities designed to improve efficiency across targeted areas of clinical research, help teams generate insights more quickly and support opportunities to reduce development timelines. AI plays an important role at AbbVie in advancing scientific innovation, strengthening connected operations and improving how medicines are discovered, developed and delivered to patients. Its partnership with Valkai builds on AbbVie's strong foundation of applying AI across R&D, helping to further scale data-driven insights and innovation. "At AbbVie, we are focused on applying AI where it can create meaningful impact for our business and, ultimately, for patients," said Nicholas Donoghoe, executive vice president, chief business and strategy officer, AbbVie. "As clinical data continues to grow in volume and complexity, partnerships like Valkai help us generate insights faster and enable our teams to spend more time on the decisions that matter most. By combining advanced AI capabilities with human expertise, we can help bring new medicines to patients more efficiently." Across AbbVie, AI serves as a critical tool to complement employee insight, enabling teams to drive strategic priorities and expedite delivery of medicines to patients, while maintaining a strong commitment to responsible and ethical use. "We're delighted to partner with AbbVie, combining advanced AI capabilities with deep scientific expertise," said Vignesh Rajendran, co-founder and chief executive officer, Valkai. "AbbVie's scale, innovation and unwavering focus on patients make this the kind of partnership that can turn bold ambition into meaningful impact." "For Clinical Sciences in particular, success depends on the ability to learn quickly, adapt intelligently and make confident decisions based on an ever-growing body of evidence," said Andrew Campbell, M.D., vice president, clinical sciences, AbbVie. "AI capabilities, like Valkai, have the potential to help us reduce time spent on manual processes and focus more attention on scientific interpretation and clinical strategy, and ultimately, the insights that can advance medicines for patients." About AI@AbbVie AI@AbbVie is AbbVie's enterprise approach to using artificial intelligence (AI) to advance scientific innovation, strengthen business outcomes and improve how medicines are discovered, developed and delivered to patients. AI is an important enabler of our mission, helping employees enhance productivity, strengthen decision-making and accelerate progress across R&D, operations and other core business functions. Guided by human expertise, responsible governance and a commitment to meaningful impact, we are embedding AI across the enterprise to accelerate innovation and help improve patients' lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. About Valkai Valkai is the AI operating system for life sciences. Its mission is to significantly accelerate time to market for the world's most critical medicines. Global Fortune 500 pharma and medtech leaders partner with Valkai to enable faster, smarter decision-making. The team hails from pioneering research and applied AI companies such as OpenAI, Google DeepMind, Sierra and Glean. AbbVie Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. | Media: Cat Langel (708) 508-3524 [email protected] | Investors: Liz Shea (847) 935-2211 [email protected] | SOURCE AbbVie Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.
AbbVie (ABBV) stock: FDA approves new Parkinson's drug Juvmo. AbbVie (ABBV) stock: FDA approves Juvmo, a new Parkinson's disease drug, ahead of its October 2026 U.S. launch. By Trader Edge September 28, 2026 3 Mins Read Tldr. * AbbVie received FDA approval for Juvmo (tavapadon), a new Parkinson's disease treatment. * Juvmo is the first selective D1/D5 receptor agonist approved for the condition. * The drug is taken once daily and can be used with or without levodopa. * Approval was based on Phase 3 TEMPO trial data showing improved daily functioning. * AbbVie plans to launch Juvmo in the U.S. in October 2026. AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA approved Juvmo, a new drug for Parkinson's disease. Juvmo is the brand name for tavapadon. It's a once daily tablet designed to help control motor symptoms in adults with Parkinson's. This approval matters because Juvmo works differently than existing options. It's the first and only selective D1/D5 receptor agonist approved for Parkinson's disease. Most current dopamine agonists target D2/D3 receptors instead. Those drugs can come with tolerability issues that limit how doctors use them. AbbVie says Juvmo gives doctors a new tool. It can be taken alone or alongside oral levodopa, the standard treatment for Parkinson's. Why this approval stands out. Levodopa remains the backbone of Parkinson's treatment. But many patients need higher and more frequent doses as the disease progresses. That escalation isn't free. It can lead to complications like dyskinesia, which are involuntary movements that affect quality of life. According to AbbVie, about 70% of Parkinson's patients see their levodopa dose increased within the first year of treatment. Juvmo may help slow that trend. In the TEMPO clinical trial program, results looked promising. After 85 weeks on Juvmo, 93% of participants hadn't needed to increase their levodopa dose. For patients with early Parkinson's, 94% hadn't started levodopa at all after the same period. Those numbers come from the open label extension phase of the trial, called TEMPO-4. What the trial data showed. The TEMPO-1 study measured daily living scores using a standard Parkinson's rating scale. Patients on Juvmo saw a 22 to 23% improvement compared to baseline. The placebo group, meanwhile, got worse by 12%. That gap was statistically significant across both tested doses. In TEMPO-3, which looked at patients already on levodopa, Juvmo increased "on" time without troublesome dyskinesia. Patients gained 1.7 hours of on time versus 0.6 hours for placebo. "Off" time, when symptoms return, also dropped more sharply with Juvmo. Patients saw a 1.9 hour reduction compared to 0.9 hours for placebo. Side effects were mostly mild to moderate. The most common included nausea, headache, dizziness, and fatigue. For patients combining Juvmo with levodopa, dyskinesia and hallucinations also showed up as common side effects. AbbVie noted the overall safety profile was described as favorable. Roopal Thakkar, AbbVie's chief scientific officer, called this the first major dopaminergic breakthrough for Parkinson's in decades. That's a notable claim given how long the treatment landscape has stayed static. Outside voices echoed the sentiment. Hubert Fernandez, a neurologist at Cleveland Clinic who worked on the TEMPO trials, said the approval gives doctors more flexibility to tailor treatment. The Michael J. Fox Foundation also weighed in. Its chief scientist, Brian Fiske, called the approval an important step in building out treatment options for Parkinson's patients. AbbVie confirmed Juvmo will be available to patients in the U.S. starting in October 2026. That's just weeks away from today's announcement. Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions - all in one powerful platform. Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants Futures & Crypto Trader | Sharing charts, strategies, & mindset tips to help you level up | Not Financial Advice Follow on X @Pro_Trader_Edge September 28, 2026